Zosano Pharma (ZSAN) Stock Analysis

What Zosano Pharma does

Zosano Pharma Corporation is a biopharmaceutical enterprise, currently in the clinical development phase, focused on supplying therapeutic agents and other biologically active substances to patients afflicted with migraine using its specialized transdermal microneedle system. Their leading experimental compound, Qtrypta (M207), represents a distinct formulation of zolmitriptan, specifically intended for the swift management of acute migraine episodes. The company commenced operations in 2006 and maintains its principal offices in Fremont, California. Notably, Zosano Pharma Corporation initiated a voluntary Chapter 11 reorganization petition with the U.S. Bankruptcy Court for the District of Delaware on June 1, 2022.

Key metrics

ETFs linked to ZSAN

Broad-market and Healthcare sector ETFs an investor holding Zosano Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ZSAN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Zosano Pharma?

Zosano Pharma trades under the ticker ZSAN on NASDAQ.

Which exchange is ZSAN listed on?

ZSAN is listed on NASDAQ.

What sector does Zosano Pharma operate in?

Zosano Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ZSAN in a portfolio?

PortView shows ZSAN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.